ScottDKelleyMD

Anesthesiology • Boston, MA

Pain Medicine

Vice President, Global Medical Affairs at Sanofi

Join to view full profile

Dr. Kelley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kelley's full profile

Already have an account?

Office
75 Francis St
Boston, MA 02115
Phone+1 617-732-8210

Fax+1 617-277-2192

Education & Training

University of California (San Francisco)Residency, Anesthesiology, 1987 - 1990
University of California (San Francisco)Residency, Internal Medicine, 1984 - 1986
University of California San Francisco School of MedicineClass of 1984

Certifications & Licensure

CA State Medical License 1986 - Present
MA State Medical License 2001 - 2026
HI State Medical License 1986 - 1992
American Board of Anesthesiology Anesthesiology

Clinical Trials

Respiration Rate V2.0 in Healthy Volunteers Start of enrollment: 2013 Feb 01
Completed

Publications & Presentations

PubMed

2 citations
Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario an...
Edgar L. Ross, Nathaniel P. Katz, Philip G. Conaghan, Alan Kivitz, Dennis C. Turk
Pain and Therapy. 2021-11-17
9 citations
Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Rand...
Alan Kivitz, Philip G Conaghan, Amy Cinar, Joelle Lufkin, Scott Kelley
Pain and Therapy. 2019-05-07
7 citations
Respiratory rate monitoring: characterizing performance for emerging technologies.
Scott D. Kelley, Michael A. E. Ramsay
Anesthesia and Analgesia. 2014-12-01

Press Mentions

Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (Triamcinolone Acetonide Extended-Release Injectable Suspension) in Bilateral Knee OA at 2018 ACR Annual MeetingOctober 22nd, 2018
Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research SymposiumAugust 20th, 2018
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. As Chief Medical OfficerDecember 12th, 2017